Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name (Descending) Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
10631-0002-31 10631-0002 isotretinoin Absorica LD 8.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Nov. 20, 2019 In Use
10631-0003-31 10631-0003 isotretinoin Absorica LD 16.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Nov. 20, 2019 In Use
10631-0004-31 10631-0004 isotretinoin Absorica LD 20.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Nov. 20, 2019 In Use
10631-0005-31 10631-0005 isotretinoin Absorica LD 24.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Nov. 20, 2019 In Use
10631-0006-31 10631-0006 isotretinoin Absorica LD 28.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Nov. 20, 2019 In Use
10631-0007-31 10631-0007 isotretinoin Absorica LD 32.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Nov. 20, 2019 In Use
71258-0015-02 71258-0015 iobenguane I-131 Azedra 15.0 mCi/mL Chemotherapy Radiopharmaceutical I 131 Intravenous July 30, 2018 In Use
71258-0015-22 71258-0015 iobenguane I-131 Azedra 15.0 mCi/mL Chemotherapy Radiopharmaceutical I 131 Intravenous July 30, 2018 In Use
72730-0101-01 72730-0101 infigratinib TRUSELTIQ 125.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral May 28, 2021 In Use
72730-0202-01 72730-0202 infigratinib TRUSELTIQ 75.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral May 28, 2021 In Use

Found 10,000 results in 2 milliseconds — Export these results